U.S. Markets closed
  • S&P 500

    4,280.15
    +72.88 (+1.73%)
     
  • Dow 30

    33,761.05
    +424.38 (+1.27%)
     
  • Nasdaq

    13,047.19
    +267.27 (+2.09%)
     
  • Russell 2000

    2,016.62
    +41.36 (+2.09%)
     
  • Crude Oil

    91.88
    -2.46 (-2.61%)
     
  • Gold

    1,799.70
    +10.00 (+0.56%)
     
  • Silver

    20.83
    +0.49 (+2.39%)
     
  • EUR/USD

    1.0257
    -0.0068 (-0.6565%)
     
  • 10-Yr Bond

    2.8490
    -0.0390 (-1.35%)
     
  • Vix

    19.53
    -0.67 (-3.32%)
     
  • GBP/USD

    1.2139
    -0.0064 (-0.5220%)
     
  • USD/JPY

    133.4800
    +0.4810 (+0.3617%)
     
  • BTC-USD

    24,489.72
    +481.52 (+2.01%)
     
  • CMC Crypto 200

    574.64
    +3.36 (+0.59%)
     
  • FTSE 100

    7,500.89
    +34.98 (+0.47%)
     
  • Nikkei 225

    28,546.98
    +727.65 (+2.62%)
     

Why Kezar Life Sciences Stock Is Crushing It Today

·1 min read
Why Kezar Life Sciences Stock Is Crushing It Today
In this article:
  • Oops!
    Something went wrong.
    Please try again later.

Shares of the clinical-stage biotech Kezar Life Sciences (NASDAQ: KZR) are soaring this morning following a positive mid-stage data readout for its lupus nephritis candidate zetomipzomib. This potentially deadly autoimmune disorder is characterized by swelling of the kidneys in patients with systemic lupus erythematosus. What appears to be driving this massive uptick in Kezar's shares today is the drug's 65% overall renal response among patients who reached the end of treatment.